DR
David Risinger Leerink Partners Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
12
Avg Return
Past Year
Past Year
9.1%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
71.4%
Neutral
28.6%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mega Cap
Over $200B
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Maintained
| $355 |
3%
upside
| 1 | +8.4% |
0
%
| 4 Feb ‘26 2 months ago |
|
|
|
Outperform
Maintained
| $60 |
2%
upside
| 1 | +6.8% |
0
%
| 13 Jan ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $525 |
22%
upside
| 3 | +12% |
0
%
| 29 Dec ‘25 3 months ago |
|
|
|
Outperform
Maintained
| $32 |
17%
upside
| 2 | +37% |
0
%
| 15 Dec ‘25 4 months ago |
|
|
|
Outperform
Maintained
| $45 |
19%
upside
| 1 | -23% |
0
%
| 11 Dec ‘25 4 months ago |
|
|
|
Outperform
Upgraded
| $1,104 |
25%
upside
| 1 | +7.1% |
0
%
| 10 Nov ‘25 5 months ago |
|
|
|
Outperform
Initiated
| $30 |
425%
upside
| 1 | -15% |
0
%
| 24 Oct ‘25 6 months ago |
|
|
|
Market Perform
Upgraded
| $70 |
7%
upside
| 1 | – |
–
| 14 Oct ‘25 6 months ago |
|
|
|
Market Perform
Downgraded
| $57 |
19%
downside
| 2 | +51% |
0
%
| 24 Sep ‘25 7 months ago |
|
|
|
Market Perform
Downgraded
| $153 |
33%
downside
| 1 | +6.1% |
–
| 13 May ‘25 11 months ago |
|